CN115397518A - 硬皮病及相关病况的治疗方法 - Google Patents

硬皮病及相关病况的治疗方法 Download PDF

Info

Publication number
CN115397518A
CN115397518A CN202180027060.0A CN202180027060A CN115397518A CN 115397518 A CN115397518 A CN 115397518A CN 202180027060 A CN202180027060 A CN 202180027060A CN 115397518 A CN115397518 A CN 115397518A
Authority
CN
China
Prior art keywords
seq
igf
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027060.0A
Other languages
English (en)
Chinese (zh)
Inventor
伊丽莎白·汤普森
斯里尼·拉马纳坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harrison Therapeutics Ireland Designated Activity Co
Original Assignee
Harrison Therapeutics Ireland Designated Activity Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harrison Therapeutics Ireland Designated Activity Co filed Critical Harrison Therapeutics Ireland Designated Activity Co
Publication of CN115397518A publication Critical patent/CN115397518A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180027060.0A 2020-02-04 2021-02-04 硬皮病及相关病况的治疗方法 Pending CN115397518A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062970063P 2020-02-04 2020-02-04
US62/970,063 2020-02-04
US202063049522P 2020-07-08 2020-07-08
US63/049,522 2020-07-08
PCT/US2021/016666 WO2021158823A1 (en) 2020-02-04 2021-02-04 Methods for the treatment of scleroderma and related conditions

Publications (1)

Publication Number Publication Date
CN115397518A true CN115397518A (zh) 2022-11-25

Family

ID=77200418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027060.0A Pending CN115397518A (zh) 2020-02-04 2021-02-04 硬皮病及相关病况的治疗方法

Country Status (11)

Country Link
US (2) US20210253686A1 (enExample)
EP (1) EP4100127A4 (enExample)
JP (1) JP2023515771A (enExample)
KR (1) KR20220151619A (enExample)
CN (1) CN115397518A (enExample)
AU (1) AU2021217378A1 (enExample)
BR (1) BR112022015447A2 (enExample)
CA (1) CA3169994A1 (enExample)
IL (1) IL295372A (enExample)
MX (1) MX2022009628A (enExample)
WO (1) WO2021158823A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025045059A1 (zh) * 2023-09-01 2025-03-06 苏州普乐康医药科技有限公司 抗igf-1r抗体或其抗原结合部分在减重中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025519600A (ja) * 2022-06-10 2025-06-26 アセリリン， インコーポレイテッド 抗ｉｇｆ－１ｒ抗体組成物
KR20250048156A (ko) * 2022-06-29 2025-04-07 리룸 테라퓨틱스, 인크. 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 사용한 자가면역 질환의 치료
WO2025007015A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for multiple sclerosis
WO2025007012A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for rheumatoid arthritis
WO2025155894A1 (en) * 2024-01-19 2025-07-24 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for fibrotic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1823163A (zh) * 2003-07-10 2006-08-23 霍夫曼-拉罗奇有限公司 针对胰岛素样生长因子ⅰ受体的抗体及其应用
US20090016967A1 (en) * 2007-05-21 2009-01-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
CN102977212A (zh) * 2004-12-22 2013-03-20 安进公司 含有抗igf-1受体抗体的组合物和获得所述抗体的方法
WO2013082254A1 (en) * 2011-12-02 2013-06-06 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596854A4 (en) * 2003-02-14 2007-06-06 Childrens Hosp & Res Ct Oak TREATMENT OF DISEASES RELATED TO REDUCED STICK OXIDE BIOVERABILITY, INCLUDING INCREASED ARGINASE
WO2010028274A1 (en) * 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
JP2012505900A (ja) * 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用
EP2647994A1 (en) * 2012-04-03 2013-10-09 Universitätsklinikum Freiburg Method for diagnosis of pulmonary involvement in systemic sclerosis
CN107982247A (zh) * 2018-01-23 2018-05-04 中日友好医院 二甲双胍在制备治疗肺纤维化药物中的应用
EP3752161A4 (en) * 2018-02-15 2021-12-22 Children's Hospital Medical Center METHOD OF TREATMENT OF FIBROSE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1823163A (zh) * 2003-07-10 2006-08-23 霍夫曼-拉罗奇有限公司 针对胰岛素样生长因子ⅰ受体的抗体及其应用
CN102977212A (zh) * 2004-12-22 2013-03-20 安进公司 含有抗igf-1受体抗体的组合物和获得所述抗体的方法
US20090016967A1 (en) * 2007-05-21 2009-01-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2013082254A1 (en) * 2011-12-02 2013-06-06 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. S. ESPINDOLA等: "Role of IGF-1R Pathway in Idiopathic Pulmonary Fibrosis", AM J RESPIR CRIT CARE MED, 21 May 2019 (2019-05-21) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025045059A1 (zh) * 2023-09-01 2025-03-06 苏州普乐康医药科技有限公司 抗igf-1r抗体或其抗原结合部分在减重中的应用

Also Published As

Publication number Publication date
KR20220151619A (ko) 2022-11-15
EP4100127A4 (en) 2024-02-28
IL295372A (en) 2022-10-01
EP4100127A1 (en) 2022-12-14
US20210253686A1 (en) 2021-08-19
MX2022009628A (es) 2022-11-07
US20240279323A1 (en) 2024-08-22
WO2021158823A1 (en) 2021-08-12
AU2021217378A1 (en) 2022-09-01
BR112022015447A2 (pt) 2022-11-16
CA3169994A1 (en) 2021-08-12
JP2023515771A (ja) 2023-04-14

Similar Documents

Publication Publication Date Title
US20240279323A1 (en) Methods for the treatment of scleroderma and related conditions
US8216571B2 (en) Fully human anti-VEGF antibodies and methods of using
EP2218461B1 (en) CD40 antibody formulation and methods
US20240287198A1 (en) Anti-cd40 antibodies for use in prevention of graft rejection
CN114286828A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
JP6596014B2 (ja) 爪および頭皮乾癬の治療方法
US20210379183A1 (en) METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY
US20230270851A1 (en) Methods for the treatment of idiopathic orbital inflammation and related conditions
KR20180008571A (ko) 다발성 골수종(mm)의 치료
CN117813114A (zh) 用于治疗甲状腺眼病的方法
CA3221817A1 (en) Combination therapies for the treatment of cancer
WO2019229155A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
EP2373335B1 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
KR20260036536A (ko) 다발성 경화증 치료를 위한 조성물 및 방법
EP4736884A1 (en) Treatment combination, and use thereof and treatment method
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
US20250000994A1 (en) Combination therapies for the treatment of non-small cell lung cancer
US20210155687A1 (en) Dosage regimen
TW202612733A (zh) 抗ＩＬ－１１Ｒα抗體在治療甲狀腺眼病中之給藥
WO2025255486A2 (en) DOSING OF ANTI-IL-11Rα ANTIBODIES IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗
HK1158977B (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination